{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:51:48Z","timestamp":1794711108881,"version":"4.9.1"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"DOI":"10.1001\/jamaoncol.2018.4060","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T16:31:57Z","timestamp":1541089917000},"page":"e184060","source":"Crossref","is-referenced-by-count":160,"title":["Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor"],"prefix":"10.1001","volume":"4","author":[{"given":"Chandrajit P.","family":"Raut","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Joseph","family":"Espat","sequence":"additional","affiliation":[{"name":"Department of Surgery, Roger Williams Medical Center, Boston University School of Medicine, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Monter Cancer Center, Northwell Health, Lake Success, New York"},{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejka M.","family":"Araujo","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Trent","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni Faith","family":"Williams","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Das","family":"Purkayastha","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"DeMatteo","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"issue":"11","key":"coi180075r1","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/annonc\/mdq773","article-title":"A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.","volume":"22","author":"Pisters","year":"2011","journal-title":"Ann Oncol"},{"key":"coi180075r2","first-page":"121","article-title":"Epidemiology, survival, and costs of localized gastrointestinal stromal tumors.","volume":"4","author":"Rubin","year":"2011","journal-title":"Int J Gen Med"},{"issue":"9574","key":"coi180075r3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","article-title":"Gastrointestinal stromal tumour.","volume":"369","author":"Rubin","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"coi180075r4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"issue":"5","key":"coi180075r5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/hupa.2002.123545","article-title":"Diagnosis of gastrointestinal stromal tumors: a consensus approach.","volume":"33","author":"Fletcher","year":"2002","journal-title":"Hum Pathol"},{"issue":"11","key":"coi180075r6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","article-title":"Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.","volume":"10","author":"Gold","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi180075r7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites.","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"issue":"10","key":"coi180075r8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","article-title":"Risk stratification of patients diagnosed with gastrointestinal stromal tumor.","volume":"39","author":"Joensuu","year":"2008","journal-title":"Hum Pathol"},{"issue":"3","key":"coi180075r9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9669","key":"coi180075r10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"coi180075r11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"issue":"36","key":"coi180075r12","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/JCO.2015.62.4304","article-title":"Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.","volume":"33","author":"Casali","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180075r13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial.","volume":"34","author":"Joensuu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi180075r14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"23","key":"coi180075r17","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi180075r19","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.","volume":"130","author":"Miettinen","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"coi180075r20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/SLA.0b013e3182a15eb7","article-title":"Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.","volume":"258","author":"DeMatteo","year":"2013","journal-title":"Ann Surg"},{"issue":"11","key":"coi180075r21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(02)00899-9","article-title":"Management of malignant gastrointestinal stromal tumours.","volume":"3","author":"Joensuu","year":"2002","journal-title":"Lancet Oncol"},{"key":"coi180075r22","doi-asserted-by":"publisher","first-page":"iii21","DOI":"10.1093\/annonc\/mdu255","article-title":"Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"25","author":"ESMO\/European Sarcoma Network Working Group","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"coi180075r23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.6004\/jnccn.2016.0078","article-title":"Soft tissue sarcoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology.","volume":"14","author":"von Mehren","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"coi180075r24","doi-asserted-by":"publisher","first-page":"10006","DOI":"10.1200\/jco.2010.28.15_suppl.10006","article-title":"Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001.","volume":"28","author":"Corless","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi180075r25","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/cncr.28669","article-title":"Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.","volume":"120","author":"Joensuu","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"coi180075r26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.","volume":"28","author":"Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)","year":"2010","journal-title":"J Clin Oncol"},{"key":"coi180075r18","volume-title":"Statistical Models and Methods for Lifetime Data","author":"Lawless","year":"2003","edition":"2nd ed"},{"key":"coi180075r15","unstructured":"Functional Assessment of Cancer Therapy\u2013General. http:\/\/www.facit.org\/FACITOrg\/Questionnaires. Accessed September 7, 2018."},{"key":"coi180075r16","unstructured":"Common Terminology Criteria for Adverse Events. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.html. Accessed September 7, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2711891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T01:45:51Z","timestamp":1662342351000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.4060"}},"subtitle":["The PERSIST-5 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.4060","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}